Merck's Enlicitide Shows Promising Results In Phase 3 CORALreef Lipids Trial

Merck & Co. (MRK) reported positive Phase 3 CORALreef Lipids trial results for its investigational oral PCSK9 inhibitor, enlicitide decanoate, demonstrating a statistically significant and clinically meaningful 55.8% reduction in LDL-C at week 24 (59.7% post-hoc) compared to placebo, with sustained efficacy through one year. The drug also showed significant improvements in non-HDL-C, ApoB, and Lp(a), while maintaining a favorable safety profile comparable to placebo. These findings position enlicitide as a promising new oral treatment option for cholesterol management in patients with atherosclerotic cardiovascular disease or statin intolerance.

Analysis

Merck & Co. (MRK) has reported highly positive initial results from its pivotal Phase 3 CORALreef Lipids trial for enlicitide decanoate, an investigational oral PCSK9 inhibitor. The drug demonstrated a statistically significant and clinically meaningful 55.8% reduction in low-density lipoprotein cholesterol (LDL-C) at week 24, with a post-hoc analysis showing an even greater 59.7% reduction versus placebo. Efficacy was sustained through one year, with a 47.6% LDL-C reduction at week 52.

Beyond LDL-C, enlicitide also achieved significant reductions in non-HDL-C (53.4%), ApoB (50.3%), and Lp(a) (28.2%) at week 24. Notably, 67.5% of treated patients reached the stringent target of at least a 50% LDL-C reduction and an LDL-C level below 55 mg/dL, compared to only 1.2% in the placebo group. This positions enlicitide as a promising oral treatment option for patients with atherosclerotic cardiovascular disease (ASCVD) or statin intolerance.

The trial highlighted a favorable safety profile, with enlicitide being well-tolerated and showing no significant differences in adverse events, serious adverse events, or mortality compared to placebo. High patient adherence (97%) further supports its potential real-world utility. These strong Phase 3 results significantly de-risk enlicitide's development and bolster MRK's cardiovascular pipeline, indicating a potential new blockbuster product with substantial market potential.

Key Decisions for Investors

• Evaluate the significant revenue potential of enlicitide, considering its strong efficacy and safety profile for ASCVD and statin-intolerant patients.
• Monitor Merck's regulatory submission process and commercial launch strategy for enlicitide, which could significantly bolster its cardiovascular franchise.
• Assess the competitive landscape for oral PCSK9 inhibitors and the potential for enlicitide to capture substantial market share.